Overview | Valuation | Financial | Ownership | Performance | Technical | ETF | ETF Perf | Custom | Charts | Tickers | Basic | TA | News | Snapshot | Maps | Stats |
| | #1 / 200 Total Type: TA:on|off Refresh: 3min | off | | | Market Cap | 49.16M | EPS (ttm) | -3.64 | P/E | - | EPS this Y | - | Forward P/E | - | EPS next Y | - | PEG | - | EPS past 5Y | -26.55% | P/S | 40.97 | EPS next 5Y | - | P/B | 2.25 | EPS Q/Q | -169.81% | Dividend | - | Sales Q/Q | -18.22% | Insider Own | 51.38% | Inst Own | 0.85% | Insider Trans | 0.00% | Inst Trans | 445.84% | Short Float | 0.15% | Earnings | Dec 22/a | Analyst Recom | 1.00 | Target Price | 80.00 | Avg Volume | 1.39M | 52W Range | 1.35 - 17.49 |
|
| | Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. It operates through the Therapeutics and Non-Therapeutics segments. The Therapeutics segment seeks to develop drug molecules and certain technologies for the treatment and diagnosis of human disease conditions. The Non-Therapeutics segment encompasses diagnostics projects including a novel molecular-based rapid pathogen identification and detection diagnostics, AML Clinic, and sale of natural supplements. Its pipeline include Smart-Act, Acticule, RPIDD, Nativus, and Claves series. The company was founded by Ian Huen on September 13, 2010 and is headquartered in London, the United Kingdom. |
| | | Ticker | PHGE [AMEX] | Company | BiomX Inc
| Country | Israel | Industry | Biotechnology |
Market Cap | 31.63M | EPS (ttm) | -0.65 | P/E | - | EPS this Y | 43.16% | Forward P/E | - | EPS next Y | 34.26% | PEG | - | EPS past 5Y | - | P/S | - | EPS next 5Y | - | P/B | 3.88 | EPS Q/Q | 42.43% | Dividend | - | Sales Q/Q | - | Insider Own | 45.46% | Inst Own | 0.77% | Insider Trans | -0.05% | Inst Trans | -0.19% | Short Float | 0.38% | Earnings | Nov 14/b | Analyst Recom | 1.00 | Target Price | 5.50 | Avg Volume | 2.46M | 52W Range | 0.19 - 0.86 |
|
| | BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage co*cktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel. | Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
---|
Oron Assaf | Chief Business Officer | Nov 29 '23 | Sale | 0.37 | 10,914 | 4,072 | 0 | Dec 01 04:46 PM | Oron Assaf | Chief Business Officer | May 22 '23 | Buy | 0.27 | 3,192 | 872 | 10,914 | May 24 06:03 AM | Oron Assaf | Chief Business Officer | May 19 '23 | Buy | 0.28 | 6,521 | 1,832 | 7,722 | May 22 04:01 PM | Oron Assaf | Chief Business Officer | May 18 '23 | Buy | 0.27 | 1,201 | 328 | 1,201 | May 22 04:01 PM |
|
| | | Ticker | SWIN [NASD] | Company | Solowin Holdings | Country | Hong Kong | Industry | Capital Markets |
Market Cap | 658.00M | EPS (ttm) | - | P/E | - | EPS this Y | - | Forward P/E | - | EPS next Y | - | PEG | - | EPS past 5Y | - | P/S | - | EPS next 5Y | - | P/B | - | EPS Q/Q | - | Dividend | - | Sales Q/Q | - | Insider Own | 82.76% | Inst Own | 0.01% | Insider Trans | 0.00% | Inst Trans | - | Short Float | 6.26% | Earnings | - | Analyst Recom | - | Target Price | - | Avg Volume | 205.88K | 52W Range | 1.84 - 65.94 |
|
| | Solowin Holdings engages in the provision of securities brokerage solutions through its subsidiary. It operates through the following segments: Securities Related Services, Investment Advisory Services, Asset Management Services, and Corporate. The Securities Related Services segment is involved in offering securities dealing and brokerage services, securities underwriting and placing services, and other financing services. The Investment Advisory Services segment offers investment solutions advisory services for clients, through a team consists of financial analysts, financial advisors, and investment managers. The Asset Management Services segment specializes in designing investment portfolios for investors with different risk appetite and to preserve the value of assets. The company was founded on July 23, 2021 and is headquartered in Hong Kong. |
| | | | Market Cap | 40.06M | EPS (ttm) | -2.71 | P/E | - | EPS this Y | - | Forward P/E | - | EPS next Y | - | PEG | - | EPS past 5Y | - | P/S | - | EPS next 5Y | - | P/B | - | EPS Q/Q | -6081.40% | Dividend | - | Sales Q/Q | - | Insider Own | 60.46% | Inst Own | 14.84% | Insider Trans | 0.01% | Inst Trans | 14.78% | Short Float | 3.83% | Earnings | - | Analyst Recom | - | Target Price | - | Avg Volume | 1.85M | 52W Range | 0.78 - 12.88 |
|
| | NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. Its product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells that have high potency as defined by parameters such as cytotoxicity, cytokine production, and activating receptor expression. The company is headquartered in Santa Ana, CA. | Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
---|
Song Paul Y. | Chief Executive Officer | Dec 07 '23 | Buy | 3.29 | 76 | 250 | 171,121 | Dec 07 05:23 PM | Song Paul Y. | Chief Executive Officer | Dec 06 '23 | Buy | 3.32 | 75 | 250 | 171,045 | Dec 07 05:23 PM | Song Paul Y. | Chief Executive Officer | Dec 05 '23 | Buy | 3.33 | 105 | 350 | 170,969 | Dec 05 03:51 PM | Graf James A | Interim CFO | Dec 04 '23 | Buy | 3.19 | 450 | 1,436 | 693 | Dec 05 03:50 PM | Song Paul Y. | Chief Executive Officer | Dec 04 '23 | Buy | 3.07 | 163 | 500 | 170,864 | Dec 05 03:51 PM |
|
| | | Market Cap | 20.88M | EPS (ttm) | -9.97 | P/E | - | EPS this Y | - | Forward P/E | - | EPS next Y | - | PEG | - | EPS past 5Y | - | P/S | 2.30 | EPS next 5Y | - | P/B | 1.22 | EPS Q/Q | -399.78% | Dividend | - | Sales Q/Q | -14.26% | Insider Own | 29.56% | Inst Own | 5.66% | Insider Trans | 0.00% | Inst Trans | -3.86% | Short Float | 1.34% | Earnings | - | Analyst Recom | 1.00 | Target Price | 6.75 | Avg Volume | 387.22K | 52W Range | 3.69 - 21.22 |
|
| | TRxADE HEALTH, Inc. is a health services information technology company, which focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey, and patient engagement in the U.S. It operates through the following segments: Trxade, Inc., CSP, Integra, and Other. The Trxade, Inc. segment is involved in web based pharmaceutical marketplace platform B2B sales. The CSP segment refers to community specialty pharmacy, LLC - Licensed retail pharmacy B2C sales. The Integra segment consists of Integra Pharma, LLC, Licensed wholesaler of brand, generic and non-drug products B2B sales. The Other segment consists of corporate overhead expense, Alliance Pharma Solutions, LLC, and Bonum Health, LLC. The company was founded by Suren Ajjarapu and Prashant Patel on July 15, 2005 and is headquartered in Lutz, FL. |
| | | | Ticker | HOVR [NASD] | Company | New Horizon Aircraft Ltd | Country | Canada | Industry | |
Market Cap | - | EPS (ttm) | 0.16 | P/E | 14.39 | EPS this Y | - | Forward P/E | - | EPS next Y | - | PEG | - | EPS past 5Y | - | P/S | - | EPS next 5Y | - | P/B | 0.36 | EPS Q/Q | 6700.00% | Dividend | - | Sales Q/Q | - | Insider Own | - | Inst Own | - | Insider Trans | - | Inst Trans | - | Short Float | 0.16% | Earnings | - | Analyst Recom | - | Target Price | - | Avg Volume | 189.76K | 52W Range | 1.00 - 12.14 |
|
| | New Horizon Aircraft Ltd. is an advanced aerospace original equipment manufacturer, which engages in the designing and aiming to build a next generation hybrid electric vertical takeoff and landing aircraft for the regional air mobility market. The company was founded on March 11, 2022 and is headquartered in Lindsay, Canada. |
| | | Market Cap | 9.45M | EPS (ttm) | -4.86 | P/E | - | EPS this Y | - | Forward P/E | - | EPS next Y | - | PEG | - | EPS past 5Y | -63.85% | P/S | 67.50 | EPS next 5Y | - | P/B | 1.50 | EPS Q/Q | 33.28% | Dividend | - | Sales Q/Q | -29.70% | Insider Own | 45.24% | Inst Own | 1.57% | Insider Trans | 0.00% | Inst Trans | - | Short Float | 14.20% | Earnings | Nov 24/b | Analyst Recom | 1.00 | Target Price | 56.00 | Avg Volume | 7.06M | 52W Range | 1.01 - 23.37 |
|
| | Rail Vision Ltd. engages in the design, development, and manufacture of a technology that focuses on cognitive vision and safety system for the railway industry. It operates through the following segments: Locomotives for Shunting Yards, Locomotives for Passenger and Freight Trains, and Light Rail Vehicle. The Locomotives for Shunting Yards segment focuses on the sale of RV200 system to shunting yard operators. The Locomotives for Passenger and Freight Trains segment promotes sales to passenger and freight train operators. The Light Rail Vehicle segment are in the process of developing an LRV system that will be designed for the light rail market segment. The company was founded by Elen Katz, Shahar Hania, Noam Teich, and Yuval Isbi in 2015 and is headquartered in Ra'anana, Israel. |
| | | | Market Cap | 74.83M | EPS (ttm) | 0.09 | P/E | 82.13 | EPS this Y | - | Forward P/E | - | EPS next Y | - | PEG | - | EPS past 5Y | - | P/S | - | EPS next 5Y | - | P/B | 2.07 | EPS Q/Q | -238.88% | Dividend | - | Sales Q/Q | - | Insider Own | 0.00% | Inst Own | 40.19% | Insider Trans | - | Inst Trans | 12.12% | Short Float | 0.00% | Earnings | - | Analyst Recom | - | Target Price | - | Avg Volume | 76.86K | 52W Range | 3.60 - 11.50 |
|
| | HCM Acquisition Corp. is a blank check company, which engages in effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It intends to identify businesses, which provide disruptive technology or innovations within the financial services industry. The company was founded on February 5, 2021 and is headquartered in Stamford, CT. |
| | | Ticker | IFBD [NASD] | Company | Infobird Co Ltd
| Country | China | Industry | Software - Application |
Market Cap | 10.22M | EPS (ttm) | -6.69 | P/E | - | EPS this Y | - | Forward P/E | - | EPS next Y | - | PEG | - | EPS past 5Y | - | P/S | 3.49 | EPS next 5Y | - | P/B | 5.61 | EPS Q/Q | 97.28% | Dividend | - | Sales Q/Q | -100.00% | Insider Own | - | Inst Own | 0.23% | Insider Trans | - | Inst Trans | - | Short Float | - | Earnings | - | Analyst Recom | 1.00 | Target Price | 9976.00 | Avg Volume | 511.07K | 52W Range | 3.44 - 576.00 |
|
| | Infobird Co. Ltd. engages in the provision of standard and customized customer relationship management cloud-based services. It offers software-as-a-service (SaaS) and business process outsourcing (BPO) services to clients, through its variable interest entity. The company was founded in 2001 and is headquartered in Beijing, China. |
| | | Market Cap | 14.94M | EPS (ttm) | - | P/E | - | EPS this Y | - | Forward P/E | - | EPS next Y | - | PEG | - | EPS past 5Y | - | P/S | - | EPS next 5Y | - | P/B | - | EPS Q/Q | - | Dividend | - | Sales Q/Q | - | Insider Own | - | Inst Own | 0.29% | Insider Trans | - | Inst Trans | - | Short Float | 0.81% | Earnings | - | Analyst Recom | - | Target Price | - | Avg Volume | 135.24K | 52W Range | 1.15 - 31.88 |
|
| | Prestige Wealth, Inc. engages in providing wealth management and asset management services. Through its subsidiaries, the firm assist its clients in identifying and purchasing well matched wealth management products and global asset management products. The company was founded by Chi Tak Sze on October 25, 2018 and is headquartered in Hong Kong. |
|
| | 123456⋯10⋯20 | |
|